JP2022537349A5 - - Google Patents

Info

Publication number
JP2022537349A5
JP2022537349A5 JP2021575326A JP2021575326A JP2022537349A5 JP 2022537349 A5 JP2022537349 A5 JP 2022537349A5 JP 2021575326 A JP2021575326 A JP 2021575326A JP 2021575326 A JP2021575326 A JP 2021575326A JP 2022537349 A5 JP2022537349 A5 JP 2022537349A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537349A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038377 external-priority patent/WO2020257416A1/en
Publication of JP2022537349A publication Critical patent/JP2022537349A/ja
Publication of JP2022537349A5 publication Critical patent/JP2022537349A5/ja
Priority to JP2025061199A priority Critical patent/JP7844707B2/ja
Pending legal-status Critical Current

Links

JP2021575326A 2019-06-19 2020-06-18 療法に使用するためのparp14の標的タンパク質分解 Pending JP2022537349A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061199A JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのparp14の標的タンパク質分解

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
US62/863,357 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061199A Division JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのparp14の標的タンパク質分解

Publications (2)

Publication Number Publication Date
JP2022537349A JP2022537349A (ja) 2022-08-25
JP2022537349A5 true JP2022537349A5 (cg-RX-API-DMAC7.html) 2023-06-27

Family

ID=71527971

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575326A Pending JP2022537349A (ja) 2019-06-19 2020-06-18 療法に使用するためのparp14の標的タンパク質分解
JP2025061199A Active JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのparp14の標的タンパク質分解

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061199A Active JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのparp14の標的タンパク質分解

Country Status (11)

Country Link
US (2) US20220388985A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986887A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537349A (cg-RX-API-DMAC7.html)
KR (1) KR102993656B1 (cg-RX-API-DMAC7.html)
CN (2) CN114206853A (cg-RX-API-DMAC7.html)
AU (1) AU2020296063B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142002A1 (cg-RX-API-DMAC7.html)
MA (1) MA56513A (cg-RX-API-DMAC7.html)
SG (1) SG11202112980TA (cg-RX-API-DMAC7.html)
WO (1) WO2020257416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
JP2024505228A (ja) * 2021-01-29 2024-02-05 ライボン・セラピューティクス・インコーポレイテッド 炎症性疾患を処置する方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
CN119923391A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN119923394A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
EP4119552A1 (en) * 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14

Similar Documents

Publication Publication Date Title
JP2007524696A5 (cg-RX-API-DMAC7.html)
ES2197167T3 (es) Imidazoles trisustituidos con multiples propiedades terapeuticas.
ES2605230T3 (es) Derivados de indazol sustituidos activos como inhibidores de cinasas
JP2008510828A5 (cg-RX-API-DMAC7.html)
JP2009532375A5 (cg-RX-API-DMAC7.html)
JP2016053042A5 (cg-RX-API-DMAC7.html)
JP2009533369A5 (cg-RX-API-DMAC7.html)
JP2008504301A5 (cg-RX-API-DMAC7.html)
HRP20040073B1 (en) Viral polymerase inhibitors
JP2007536231A5 (cg-RX-API-DMAC7.html)
GB0113233D0 (en) Chemical compounds
JP2008540574A5 (cg-RX-API-DMAC7.html)
JP2018529690A5 (cg-RX-API-DMAC7.html)
JP2003508394A5 (cg-RX-API-DMAC7.html)
JP2014524441A5 (cg-RX-API-DMAC7.html)
JP2006522037A5 (cg-RX-API-DMAC7.html)
JP2016500653A5 (cg-RX-API-DMAC7.html)
JP2024532768A5 (cg-RX-API-DMAC7.html)
JP2015535847A5 (cg-RX-API-DMAC7.html)
JP2010520214A5 (cg-RX-API-DMAC7.html)
JP2017530193A5 (cg-RX-API-DMAC7.html)
EA200971063A1 (ru) Ариламидпиримидоновые соединения
JP2023532128A5 (cg-RX-API-DMAC7.html)
JP4268871B2 (ja) ピリミジノン化合物及びその薬剤として許容される塩の製造方法
JP2023504542A5 (cg-RX-API-DMAC7.html)